Skip to content
Dosage GuideResearch Reference

Tabimorelin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Tabimorelin. All information is for educational purposes only.

Quick Answer

Tabimorelin was studied at oral doses of 5–25 mg in clinical trials to stimulate growth hormone release. Dosing was typically once daily. As tabimorelin development was discontinued, no established clinical dosage recommendations exist. Research doses were selected to elicit a GH response while minimizing side effects.

→ Tabimorelin Benefits→ Tabimorelin Side Effects→ Full Tabimorelin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 5–25 mg (oral)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Growth Hormone Deficiency (Research)

5–25 mg1× daily
Duration

Variable (clinical trials used short-term dosing)

Oral administration. Doses were titrated based on individual GH response in clinical studies. No established long-term treatment protocol exists.

IGF-1 Elevation (Research)

10–25 mg1× daily
Duration

Variable (clinical trials used short-term dosing)

Oral administration. Higher doses were used to maximize IGF-1 response. Clinical trials measured IGF-1 levels after dosing.

Growth Hormone Stimulation (Research)

5–15 mg1× daily
Duration

Single dose or short term

Oral administration. Lower doses might be sufficient for GH stimulation without significant side effects. Acute GH response was the primary outcome measured in studies.

Timing & Frequency

Clinical trials typically administered tabimorelin in the morning. The relatively short half-life of ~2-3 hours suggests a single daily dose provides a transient GH pulse.

Cycle Guidance

Given the limited development of tabimorelin, there is no established cycling guidance. Clinical trials did not study long-term continuous dosing. Cycling might be considered to mitigate potential desensitization or receptor downregulation, but this is speculative.

Reconstitution Reference

Quick reference for reconstituting Tabimorelin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (oral formulation)
BAC Water VolumeN/A
Concentration & DrawN/A
StorageN/A
StabilityN/A
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What was the typical dose of tabimorelin in clinical trials?
Clinical trials used oral doses of tabimorelin ranging from 5–25 mg once daily to stimulate growth hormone release and IGF-1 elevation in adults with growth hormone deficiency.
Is there a recommended long-term dosage for tabimorelin?
No, there is no established long-term dosage for tabimorelin. The compound did not progress beyond Phase 2 clinical trials. Dosage selection remains investigational.
How often was tabimorelin administered?
Tabimorelin was administered orally once daily in clinical trials. The short half-life suggests a single dose produces a relatively short burst of GH stimulation.

Last updated: 2026-02-19